Showing 2951-2960 of 6036 results for "".
- Roche’s Actemra/RoActemra Cuts Need for Ventilator Use in COVID-19 Pneumoniahttps://modernod.com/news/roches-actemra-roactemra-cuts-need-for-ventilator-use-in-covid-19-pneumonia/2478299/Roche announced results from the EMPACTA study on Friday, showing that patients with COVID-19-associated pneumonia who had Actemra/RoActemra (tocilizumab) added to standard care were 44% less likely to progress to mechanical ventilation or death compared to placebo plus standard care, meeting the
- Keeler Partners With Medical Device Maker Olleyeshttps://modernod.com/news/keeler-partners-with-medical-device-maker-olleyes/2478278/Keeler has announced a partnership with Olleyes, a developer of eye care-based office and home-based diagnostic products. Terms of the deal were not disclosed. Olleyes is the maker of VisuALL VRP (Virtual Reality Perimetry), a platform designed for standardized and mobile assessment
- First Patient Dosed in Phase 3 Clinical Trial of Dextenza for the Treatment of Post-Surgical Ocular Inflammation and Pain in Childrenhttps://modernod.com/news/ocular-therapeutix-announces-first-patient-dosed-in-phase-3-clinical-trial-of-dextenza-for-the-treatment-of-post-surgical-ocular-inflammation-and-pain-in-children/2478274/Ocular Therapeutix announced that it has dosed the first patients in a phase 3 clinical trial of Dextenza (dexamethasone ophthalmic insert) 0.4 mg for the treatment of post-surgical ocular inflammation and pain in children following cataract surgery. “We are pleased to announce the start o
- Staar Surgical Announces Completion of Patient Enrollment in EVO Implantable Lens US Clinical Trialhttps://modernod.com/news/staar-surgical-announces-completion-of-patient-enrollment-in-evo-implantable-lens-us-clinical-trial/2478275/Staar Surgical has announced that patient enrollment for the primary study analysis cohort of 300 subjects has been achieved in its FDA clinical trial, “A Multicenter Clinical Evaluation of the EVO/EVO+ Visian Implantable Collamer Lens.” Primary study analysis will be conducted when 300 primary e
- Researchers Are Able to Visualize the Retina’s Function at the Cellular Levelhttps://modernod.com/news/researchers-are-able-to-visualize-the-retinas-function-at-the-cellular-level/2478271/While there is no cure for blindness and macular degeneration, scientists have accelerated the process to find a cure by visualizing the inner workings of th
- Kala Pharmaceuticals to Host Key Opinion Leader Symposium on Unmet Need in Dry Eye Disease and Potential for Eysuvishttps://modernod.com/news/kala-pharmaceuticals-to-host-key-opinion-leader-symposium-on-unmet-need-in-dry-eye-disease-and-potential-for-eysuvis/2478270/Kala Pharmaceuticals announced that it will host a key opinion leader symposium on the unmet need in dry eye disease and the potential for Eysuvis as a short-term treatment for the signs and symptoms of the disease. The event will be held virtually on Thursday, September 17, 2020, beginning at 8
- Visible Genomics Launches DNA Age-Related Macular Degeneration Testinghttps://modernod.com/news/visible-genomics-launches-dna-age-related-macular-degeneration-testing/2478264/Visible Genomics, a Chicago-area genetics testing company, has announced the launch of a new noninvasive genetic eye test that the company says determines a patient’s likelihood of contracting age-related macular degeneration (AMD). While it’s estimated that up to 70% of AMD cases are due
- AGTC Provides Trial Design Update for its Phase 2/3 XLRP Clinical Trialhttps://modernod.com/news/agtc-provides-trial-design-update-for-its-phase-2-3-xlrp-clinical-trial/2478261/Applied Genetic Technologies Corporation provided additional information about the proposed design of the planned phase 2/3 trial for its X-linked retinitis pigmentosa (XLRP) clinical program, which is expected to commence in the first quarter of 2021, and new preliminary data on
- Zeiss Launches “Vision in County” Cataract Development Program in Shandong, Chinahttps://modernod.com/news/zeiss-launches-vision-in-county-cataract-development-program-in-shandong-china/2478256/The “Vision in County” Cataract Development Program by Zeiss was officially launched in Shandong, China on September 3, 2020. At the event, the first training base was established in the Affiliated Eye Hospital of
- Ocular Therapeutix Announces Resolution of FDA Warning Letter Related to ReSure Sealanthttps://modernod.com/news/ocular-therapeutix-announces-resolution-of-fda-warning-letter-related-to-resure-sealant/2478250/Ocular Therapeutix announced it has received a letter from the FDA, dated September 2, 2020, closing out the Warning Letter it received from the FDA on October 18, 2018 concerning ReSure Sealant. The violation cited in Warning Letter (CMS #564663) has been addressed and Ocular is committed to sus